entertainment -WSS

entertainment

author：entertainment 2025-09-28 07:21:51 - browse：26628

Yichuan Cao/Sipa USA via AP Images

Gilead Sciences said Monday that Trodelvy, its “smart-bomb” medicine that combines an antibody with chemotherapy, did not significantly extend the lives of patients with metastatic non-small cell lung cancer when given after a first treatment failed.

The result, from a closely watched study called Evoke-01, will be seen as a disappointment by investors and oncologists alike.

Drugs like Trodelvy, known as antibody drug conjugates, are one of the hottest areas in oncology. The idea is that these medicines combine an antibody, which is triggered when it binds to a protein on a cancer cell, with a “payload” of chemotherapy that poisons the cancer.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： A new nitrogen execution bill also undermines medical licensing

hotspot

WSS

PBM reform efforts get punted in Congress

Obesity drugs seen as possible treatment for liver disease MASH

Medicare inequities exacerbate Puerto Rico’s health disparities

PBM reform efforts get punted in Congress

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

How Long Island became the ‘eugenics capital of the world’

explore

entertainment

hotspot

How to save PrEP access — and even expand it

How to make Best Hospitals ratings actually useful for patients

In age of alternative facts, a scholarly course on calling out crap

Alabama IVF ruling threatens families facing fatal genetic disease

Moonlake's readout produced a cash windfall. Risks remain

New documents shed light on MD Anderson Cancer Institute feud

BioMarin wins approval for gene therapy to treat hemophilia A

AstraZeneca bets AAV gene therapy will still deliver the goods

Cancer drug shortages should be causing more outrage

Obesity drugs seen as possible treatment for liver disease MASH

leisure time

Why palliative psychiatry is worth discussing

FDA panel gives mixed vote on blood pressure devices

CDC advisory panel says seniors 'may' get RSV vaccine

A new nitrogen execution bill also undermines medical licensing

How to make AI work for medicine

In science, is the line between industry and academia shifting?

knowledge

hotspot

hotspot

knowledge